HUMAN PLACENTAL TRANSFER OF HUMAN GROWTH HORMONE-I125

PEDIATRICS ◽  
1971 ◽  
Vol 48 (4) ◽  
pp. 534-539
Author(s):  
Katherine C. King ◽  
Peter A. J. Adam ◽  
Robert Schwartz ◽  
Kari Teramo
Keyword(s):  
Growth Hormone ◽  
Plasma Concentration ◽  
Amniotic Fluid ◽  
Human Growth Hormone ◽  
Anterior Pituitary ◽  
Placental Transfer ◽  
Human Growth ◽  
Maternal Plasma ◽  
Fetal Plasma ◽  
Arterial Plasma

At term, human growth hormone (HGH) does not cross the human placenta: therefore, the source of HGH in the fetal plasma is the fetal pituitary. In order to determine whether the fetal pituitary is also the only source of HGH secretion early in gestation, the maternofetal transfer of HGH-I125 was evaluated in four pregnant women receiving legal therapeutic abortions by abdominal hysterotomy. The plasma concentration of HGH-I125 was maintained until fetal delivery by a continuous infusion of the labeled hormone at 20 µc/hr for 170 to 225 minutes; and the plasma HGH-I125 concentration was determined by a specific immunoprecipitation. Even with maternal plasma levels of radioactive HGH between 875 and 1287 cpm/ml, no HGH-I125 was detected in either umbilical venous or arterial plasma, or in the amniotic fluid. As at term, no human placental transfer of HGH-I125 occurs early in gestation. Since the fetal hypophysis synthesizes, secretes, and stores HGH as early as 9 weeks in gestation, the fetal anterior pituitary apparently is the only source of HGH available to the human fetus.

Placental transfer of indomethacin in the rabbit and sheep

1981 ◽  
Vol 59 (4) ◽  
pp. 342-346 ◽  
Author(s):  
W. H. Harris ◽  
G. R. Van Petten
Keyword(s):  
Plasma Concentration ◽  
Amniotic Fluid ◽  
Intravenous Infusion ◽  
Plasma Proteins ◽  
Placental Transfer ◽  
Plasma Concentrations ◽  
Maternal Plasma ◽  
Fetal Plasma ◽  
Maximal Plasma ◽  
Pregnant Ewe

The placental transfer of indomethacin was studied in the rabbit at 30 days of gestation and in the sheep between 120 and 135 days of gestation. Plasma concentrations of indomethacin reached a maximum of 13.7 ± 1.6 and 10.9 ± 1.5 μg/mL in the doe and fetuses, respectively, at 1 h following a maternal subcutaneous injection of 10.0 mg/kg. The maternal plasma concentration of drug decreased rapidly but the fetal plasma concentration of drug remained elevated and exceeded that of the doe before decreasing. Indomethacin became detectable in the amniotic fluid after 2 h, reached a maximum of 3.2 ± 0.8 μg/mL at 4 h, and then gradually decreased. The intravenous infusion of 10.0 mg of indomethacin per kilogram over 30 min into a pregnant ewe resulted in a maximal plasma concentration of 13.5 ± 0.7 μg/mL in the ewe and 0.6 ± 0.1 μg/mL in the fetus at the termination of the infusion. The concentration of indomethacin in the amniotic fluid increased to a maximum of 3.5 ± 0.5 μg/mL 150 min after the infusion stopped. There was an increase in the percentage of drug bound by the fetal plasma proteins as gestation advanced. Thus there exists the possibility that the fetus would be exposed to increasing amounts of indomethacin as term approached.

Effects of a fragment of human growth hormone-releasing factor in normal and 'Little' mice

1985 ◽  
Vol 106 (1) ◽  
pp. 1-5 ◽  
Author(s):  
R. G. Clark ◽  
I. C. A. F. Robinson
Keyword(s):  
Growth Hormone ◽  
Growth Rate ◽  
Pituitary Gland ◽  
Human Growth Hormone ◽  
Anterior Pituitary ◽  
Human Growth ◽  
Body Growth ◽  
Stimulus Secretion Coupling ◽  
And Storage ◽  
Little Mouse

ABSTRACT The 'Little' mouse is characterized by a body growth rate 60% of normal due to a defect in the synthesis and storage of GH in the anterior pituitary gland. We have now investigated the effects of GH releasing factor (GRF) in these mice and in normal animals. The pituitary GH content in Little mice was only 4% of that in normal C57: +/+ mice, and was not affected by twice daily i.p. injections of human (h) GRF1-29NH2 (0·2−2 μg) for 14 days. This treatment also had no effect on body growth. In anaesthetized normal mice, single i.v. injections of 0·1 or 2 μg hGRF1-29NH2 released large amounts of GH into the plasma, whereas this peptide was ineffective in Little mice, whether or not they had been pretreated with GRF. Therefore, although pituitaries of Little mice contain significant amounts of GH, this pool is not releasable by GRF. This suggests that the dwarfism in Little mice may be partly due to a pituitary defect in GRF receptors or their stimulus-secretion coupling, rather than a deficiency in hypothalamic GRF. J. Endocr. (1985) 106, 1–5

scholarly journals Molecular cloning, heterological expression and production of the human growth hormone

2019 ◽  
Vol 55 (2) ◽  
pp. 182-187
Author(s):  
A. M. Gorkavaya ◽  
A. A. Gilep ◽  
G. V. Sergeev
Keyword(s):  
Growth Hormone ◽  
Cell Proliferation ◽  
Molecular Cloning ◽  
Human Growth Hormone ◽  
Anterior Pituitary ◽  
Bacterial Culture ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Biochemical Pathways ◽  
His Tag

Growth hormone (GH) is a polypeptide produced in the anterior pituitary lobe that triggers different biochemical pathways and increases cell proliferation and growth. In this work, the pNic based vector for periplasmatic secretion was developed. Recombinant human growth hormone was produced via periplasmatic secretion (42h, 30 °С) followed by several steps of purification. GH obtained does not contain His-tag. Expression level of 2,85 mg per1 literof bacterial culture was achieved.

THE RESPONSE OF THE MAMMARY GLAND OF THE MALE MOUSE TO PROGESTERONE AND HUMAN MAMMOTROPHIC SUBSTANCES

1959 ◽  
Vol 18 (1) ◽  
pp. 26-31 ◽  
Author(s):  
E. F. SCOWEN ◽  
J. HADFIELD ◽  
E. M. DONATH
Keyword(s):  
Growth Hormone ◽  
Mammary Gland ◽  
Pituitary Gland ◽  
Human Growth Hormone ◽  
Human Urine ◽  
Male Mouse ◽  
Anterior Pituitary ◽  
Human Growth ◽  
Anterior Pituitary Gland ◽  
The Other

SUMMARY 1. Five strains of mice primarily insensitive to mammotrophic substances in human urine and anterior pituitary gland were all equally sensitive to the mammotrophic action of progesterone. The sensitive Strong A 2 strain also reacted to progesterone. The reaction in this strain was somewhat enhanced when compared with the other five strains. 2. Two insensitive strains became responsive to the human mammotrophic substances after treatment with progesterone. The response to human whole anterior pituitary substance after progesterone was present and enhanced in the sensitive Strong A 2 strain. 3. A preparation of human growth hormone produced a mammotrophic response in the mouse similar to that of human whole pituitary. Within the limits of the experiment the major mammotrophic potency of the pituitary appeared to be extracted in the growth hormone fraction.

Localization of Fluorescent Antibodies to Human Growth Hormone in Human Anterior Pituitary Glands.

1960 ◽  
Vol 104 (2) ◽  
pp. 232-235 ◽  
Author(s):  
A. Leznoff ◽  
J. Fishman ◽  
L. Goodfriend ◽  
E. McGarry ◽  
J. Beck ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Anterior Pituitary ◽  
Human Growth ◽  
Pituitary Glands ◽  
Human Anterior Pituitary
Sign in / Sign up

Export Citation Format

Share Document